Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 3/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23744451 | 0.95 | HCAR2 (0.44) | CHRM2CHRM1HCAR2CCR3CHRM4 | |
| SCHEMBL23744471 | 0.94 | CHRM4 (0.38) | CHRM2CHRM1HCAR2CCR1CCR3 | |
| SCHEMBL23744736 | 0.93 | PRKAA2 (0.41) | CCR1CCR3PRKAA2 | |
| SCHEMBL23744723 | 0.92 | HCAR2 (0.47) | CHRM2CHRM1HCAR2CCR1CCR3 | |
| SCHEMBL30345503 | 0.89 | HCAR2 (0.37) | HCAR2CCR1ENPP2PTGDR2 | |
| SCHEMBL26429666 | 0.89 | HCAR2 (0.37) | HCAR2CCR1ENPP2PTGDR2 | |
| SCHEMBL23744259 | 0.86 | HCAR2 (0.51) | CHRM2CHRM1HCAR2CHRM4 | |
| SCHEMBL23744257 | 0.86 | HCAR2 (0.51) | CHRM2CHRM1HCAR2CHRM4 | |
| SCHEMBL23744636 | 0.86 | CHRM2 (0.46) | CHRM2CHRM1HCAR2CHRM4 | |
| SCHEMBL23744584 | 0.85 | HCAR2 (0.42) | HCAR2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | CHRM2 2/4885CHRM1 5/4885HCAR2 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.